Abstract 140P
Background
Periampullary carcinoma accounts for over 30,000 cancer-related deaths per year in the US. The outcome of the disease differs according to the chosen modality of treatment. This study compared the survival rate between patients undergoing pancreaticoduodenectomy alone versus those receiving neoadjuvant chemotherapy before undergoing the surgery in stage II and III periampullary carcinoma.
Methods
Using the SEER database, we extracted the data of 868 patients with periampullary carcinoma from 2007 to 2011, aged between 40-79 years old. We selected patients with periampullary carcinomas who underwent pancreaticoduodenectomy alone compared to those received neoadjuvant chemotherapy before the surgery.
Results
The highest 5-year survival rate was observed in patients receiving neoadjuvant chemotherapy followed by pancreaticoduodenectomy (20.1%); especially those of stage II (20.1%). However, we found no significant difference in overall survival regarding the patients' gender or race.Table:
140P
Variables | Overall survival | p-value |
---|---|---|
Therapy Surgery Combined | 17.3% 20.1% | 0.000** |
Stage II III | 20.1% 7.9 % | 0.000** |
Race White Black | 19.0% 22.7% | 0.732 |
Sex Male Female | 19.3% 19.5% | 0.388 |
Highly significant p-value at ≤ 0.001 Combined: neoadjuvant chemotherapy and surgery.
Conclusions
Patients receiving neoadjuvant chemotherapy before pancreaticoduodenectomy had better 5-year overall survival compared to those undergoing pancreaticoduodenectomy alone; especially stage II.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Mai Abdelkader.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
133P - Prognostic and predictive factors from the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in previously treated advanced hepatocellular carcinoma (aHCC)
Presenter: Thomas Yau
Session: Poster display session
Resources:
Abstract
134P - Identification, development and validation of a circulating miRNA-based diagnostic signature for early detection of gastric cancer
Presenter: Daisuke Izumi
Session: Poster display session
Resources:
Abstract
135P - The promising key genes associated with tumour microenvironment and prognosis of hepatocellular carcinoma
Presenter: Jing Fang
Session: Poster display session
Resources:
Abstract
136P - Helicobacter pylori-positive gastric diffuse large B-cell lymphoma: A subset with distinct prognostic features
Presenter: Yuan Cheng
Session: Poster display session
Resources:
Abstract
137P - Significant benefit of pyrotinib combined with SHR6390 in patients with multiline-resistant HER2-positive advanced gastric cancer
Presenter: Zuhua Chen
Session: Poster display session
Resources:
Abstract
138P - Incidence of supracarinal lymph node positivity in operated cases of total esophagectomy: Short term results from a tertiary cancer centre
Presenter: Akhil Palod
Session: Poster display session
Resources:
Abstract
139P - Prognostic usefulness of advanced lung cancer inflammation index in locally-advanced pancreatic carcinoma patients treated with radical chemoradiotherapy
Presenter: Ayberk Besen
Session: Poster display session
Resources:
Abstract
141P - A 13-gene signature of DNA repair predicts prognosis in gastric cancer patients
Presenter: Jinjia Chang
Session: Poster display session
Resources:
Abstract
142P - Relation between Interleukin -4 (590C/T) gene polymorphism and hepatocellular carcinoma risk in HBV and HCV patients
Presenter: Suzy Gohar
Session: Poster display session
Resources:
Abstract
143P - NOTCH3 expression predicts poor survival in advanced esophageal squamous cell cancers
Presenter: Raja Pramanik
Session: Poster display session
Resources:
Abstract